C6orf146 Inhibitors
Chemical inhibitors of C6orf146 can disrupt its function through various mechanisms by targeting the signaling pathways in which this protein is involved. Staurosporine operates by broadly inhibiting protein kinases, which are essential for phosphorylation processes that activate proteins downstream, including C6orf146. Consequently, staurosporine can impede the functional role of C6orf146 by preventing the activation of kinases necessary for its activity. Erlotinib and gefitinib, both EGFR tyrosine kinase inhibitors, can directly inhibit the function of C6orf146 by targeting EGFR, which plays a critical role in the signaling cascade that C6orf146 is part of. Similarly, lapatinib, which inhibits both EGFR and HER2 tyrosine kinases, can also suppress C6orf146 function by disrupting upstream signaling events.
Moreover, sorafenib and sunitinib can inhibit the function of C6orf146 through their action on multiple kinases involved in the Ras/Raf/MEK/ERK pathway and receptor tyrosine kinases, respectively. These pathways are crucial for cell proliferation and survival signaling in which C6orf146 participates. Dasatinib, by inhibiting Src-family kinases and c-Kit, can affect C6orf146 function by blocking the signaling processes upstream. U0126 can specifically inhibit MEK1/2, thus hindering the MAPK/ERK pathway and consequently the function of C6orf146. LY294002, by inhibiting PI3K, and rapamycin, by inhibiting mTOR, can both disrupt the PI3K/Akt/mTOR pathway, which is essential for the activity of C6orf146. Lastly, SB203580 and SP600125 can inhibit the p38 MAP kinase and JNK, respectively, affecting pathways in which C6orf146 operates and thus can inhibit its function by impeding necessary signaling events.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine inhibits a wide range of protein kinases. C6orf146's function could be compromised as staurosporine inhibits kinases that phosphorylate substrates necessary for C6orf146 activity, leading to its functional inhibition. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
Erlotinib targets the epidermal growth factor receptor (EGFR) tyrosine kinase. C6orf146, known to be involved in EGFR signaling, would be inhibited in function as erlotinib impedes EGFR activity, which is vital for C6orf146's role in cellular signaling processes. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib inhibits multiple kinases involved in the Ras/Raf/MEK/ERK pathway, which is crucial for cell proliferation and survival. C6orf146, participating in this pathway, would be functionally inhibited as sorafenib disrupts signaling required for its activity. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is an inhibitor of receptor tyrosine kinases, which are part of signaling pathways that C6orf146 is involved in. By inhibiting these kinases, sunitinib impairs pathways that are essential for C6orf146's functional role in the cell. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib inhibits Src-family kinases and c-Kit, which are involved in multiple signaling pathways. As C6orf146 functions downstream of these kinases, its activity would be functionally inhibited when dasatinib disrupts these signaling cascades. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 specifically inhibits MEK1/2, key components in the MAPK/ERK pathway. C6orf146, which operates within this pathway, would be functionally inhibited as U0126 blocks MEK1/2 activation, which in turn is necessary for C6orf146's role in signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, affecting the Akt signaling pathway. C6orf146, involved in the PI3K/Akt pathway, would experience functional inhibition as LY294002 disrupts PI3K activity, which is a prerequisite for C6orf146's role within this signaling network. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a central component of the PI3K/Akt/mTOR pathway. As mTOR is necessary for full activation of several proteins and C6orf146 is part of this pathway, inhibition by rapamycin would lead to functional inhibition of C6orf146 by preventing its required activation or signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. With p38 MAP kinase being a signaling molecule in pathways involving C6orf146, inhibition by SB203580 would lead to a functional inhibition of C6orf146 by impeding the signaling processes that it relies on. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 inhibits JNK, affecting the JNK signaling pathway. C6orf146, which is active within this pathway, would be functionally inhibited by SP600125 as it blocks JNK activity, which is necessary for the signaling events that involve C6orf146. | ||||||